Updated TRUST-I and TRUST-II data show durable taletrectinib responses in ROS1+ NSCLC regardless of prior chemotherapy or fusion partner.
Commentary|Articles|September 22, 2026
What to Watch at IMS 2026: Defining Cure as Multitargeting, CELMoDs, and In Vivo CAR T Move Forward
Author(s)Jonah Feldman
Fact checked by: Sabrina Serani
Preview the 2026 International Myeloma Society meeting: the IMS/IMWG cure consensus, plenary session phase 3 trials, and new bispecific/CAR T myeloma findings.
Advertisement
Advertisement
The 23rd International Myeloma Society (IMS) Annual Meeting & Exposition, taking place September 23-26, 2026, in Glasgow, Scotland, will showcase a number of key trials in the newly diagnosed and relapsed settings, including new bispecific antibodies, cereblon E3 ligase modulators (CELMoDs), and multitargeting combinations. Notably, it will devote much of its scientific program to a question that has taken hold in the myeloma community over the past year: how close has multiple myeloma (MM) come to being a curable disease?
Related to this article
During a live event, Sikander Ailawadhi, MD, and participants considered a case patient with relapsed multiple myeloma after a quadruplet induction who declined CAR T-cell therapy.
Results from the phase 3 MAVERICK trial (SWOG S1827) show MRI surveillance alone improved cognitive failure-free survival vs adding PCI in SCLC.
The COPERNICUS study of amivantamab/lazertinib showed lower rates of adverse events and discontinuation with supportive care regimens in patients with EGFR-mutated non–small cell lung cancer.
The B7-H3–targeted antibody-drug conjugate tambotatug pelitecan significantly reduced the risk of death in patients with small cell lung cancer.
KEYNOTE-D46 shows sacituzumab govitecan plus pembrolizumab misses PFS/OS targets in PD-L1–high metastatic NSCLC, despite higher responses and toxicity.
The phase 3 DESTINY-Lung04 trial showed first-line trastuzumab deruxtecan extended PFS in patients with HER2-mutant NSCLC.
Updated PRESERVE-003 data showed gotistobart nearly doubled median OS vs docetaxel in previously treated squamous NSCLC.
Advertisement
Advertisement